147 related articles for article (PubMed ID: 11972397)
1. Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients.
Silins I; Avall-Lundqvist E; Tadesse A; Jansen KU; Stendahl U; Lenner P; Zumbach K; Pawlita M; Dillner J; Frankendal B
Gynecol Oncol; 2002 May; 85(2):333-8. PubMed ID: 11972397
[TBL] [Abstract][Full Text] [Related]
2. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients.
de Boer MA; Jordanova ES; Kenter GG; Peters AA; Corver WE; Trimbos JB; Fleuren GJ
Clin Cancer Res; 2007 Jan; 13(1):132-8. PubMed ID: 17200347
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus-related serological markers of invasive cervical carcinoma in Brazil.
Sun Y; Eluf-Neto J; Bosch FX; Muñoz N; Booth M; Walboomers JM; Shah KV; Viscidi RP
Cancer Epidemiol Biomarkers Prev; 1994 Jun; 3(4):341-7. PubMed ID: 8061584
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis.
Wang-Johanning F; Lu DW; Wang Y; Johnson MR; Johanning GL
Cancer; 2002 Apr; 94(8):2199-210. PubMed ID: 12001118
[TBL] [Abstract][Full Text] [Related]
5. The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer.
Fisher SG; Benitez-Bribiesca L; Nindl I; Stockfleth E; Muller M; Wolf H; Perez-Garcia F; Guzman-Gaona J; Gutierrez-Delgado F; Irvin W; Gissmann L
Gynecol Oncol; 1996 Apr; 61(1):73-8. PubMed ID: 8626121
[TBL] [Abstract][Full Text] [Related]
6. HPV-16-related proteins as the serologic markers in cervical neoplasia.
Park JS; Park DC; Kim CJ; Ahn HK; Um SJ; Park SN; Kim SJ; Namkoong SE
Gynecol Oncol; 1998 Apr; 69(1):47-55. PubMed ID: 9570998
[TBL] [Abstract][Full Text] [Related]
7. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma.
Ressler S; Scheiden R; Dreier K; Laich A; Müller-Holzner E; Pircher H; Morandell D; Stein I; Viertler HP; Santer FR; Widschwendter A; Even J; Jansen-Dürr P; Capesius C; Zwerschke W
Clin Cancer Res; 2007 Dec; 13(23):7067-72. PubMed ID: 18056184
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
Walboomers JM; Jacobs MV; Manos MM; Bosch FX; Kummer JA; Shah KV; Snijders PJ; Peto J; Meijer CJ; Muñoz N
J Pathol; 1999 Sep; 189(1):12-9. PubMed ID: 10451482
[TBL] [Abstract][Full Text] [Related]
9. Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy.
Kim JY; Park S; Nam BH; Roh JW; Lee CH; Kim YH; Shin HJ; Lee SK; Kong SY; Seong MW; Han TJ; Lee MY; Cho KH; Park SY
J Clin Oncol; 2009 Oct; 27(30):5088-93. PubMed ID: 19770372
[TBL] [Abstract][Full Text] [Related]
10. Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations.
Nindl I; Zumbach K; Pawlita M; Teller K; Schneider A; Dürst M
J Infect Dis; 2000 May; 181(5):1764-7. PubMed ID: 10783118
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus antibody responses among patients with incident cervical carcinoma.
Wang Z; Konya J; Avall-Lundkvist E; Sapp M; Dillner J; Dillner L
J Med Virol; 1997 Aug; 52(4):436-40. PubMed ID: 9260694
[TBL] [Abstract][Full Text] [Related]
12. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia.
Zumbach K; Kisseljov F; Sacharova O; Shaichaev G; Semjonova L; Pavlova L; Pawlita M
Int J Cancer; 2000 Feb; 85(3):313-8. PubMed ID: 10652419
[TBL] [Abstract][Full Text] [Related]
13. HPV prevalence, E6 sequence variation and physical state of HPV16 isolates from patients with cervical cancer in Sichuan, China.
Qiu AD; Wu EQ; Yu XH; Jiang CL; Jin YH; Wu YG; Chen Y; Chen Y; Shan YM; Zhang GN; Fan Y; Zha X; Kong W
Gynecol Oncol; 2007 Jan; 104(1):77-85. PubMed ID: 16970982
[TBL] [Abstract][Full Text] [Related]
14. [Expression, purification, and serum antibody detection of HPV16 E6 in cervical cancer patients].
Gao YE; Guo JZ; Zhang J; Song TB; Yan XJ
Ai Zheng; 2006 Nov; 25(11):1374-9. PubMed ID: 17094904
[TBL] [Abstract][Full Text] [Related]
15. HPV 16 E7 antibody levels in cervical cancer patients: before and after treatment.
Di Lonardo A; Marcante ML; Poggiali F; Venuti A
J Med Virol; 1998 Mar; 54(3):192-5. PubMed ID: 9515768
[TBL] [Abstract][Full Text] [Related]
16. The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix.
Song SH; Lee JK; Seok OS; Saw HS
Gynecol Oncol; 2007 Mar; 104(3):732-8. PubMed ID: 17188341
[TBL] [Abstract][Full Text] [Related]
17. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
18. Serological study in Tunisian cervical cancer patients.
Achour M; Kochbati L; Zeghal D; Kahla S; Maalej M; Zouari F; Oueslati R
Pathol Biol (Paris); 2009 Jul; 57(5):415-9. PubMed ID: 18586408
[TBL] [Abstract][Full Text] [Related]
19. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.
Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D
Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange.
Subbaramaiah K; Dannenberg AJ
Cancer Res; 2007 Apr; 67(8):3976-85. PubMed ID: 17440114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
